{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T20:39:23Z","timestamp":1790973563392,"version":"4.1.0"},"reference-count":94,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Non-tuberculous mycobacteria (NTM) comprise more than 190 species capable of causing severe pulmonary, lymphatic, cutaneous, and disseminated infections, particularly in immunocompromised populations. Over the past two decades, the global incidence of NTM infections has risen steadily, underscoring an urgent unmet medical need. Treatment remains highly challenging due to intrinsic antimicrobial resistance and the requirement for prolonged multidrug regimens that are often poorly tolerated and associated with unsatisfactory outcomes. At the same time, the development of novel therapies has lagged behind other disease areas, hindered by the high costs of antimicrobial drug discovery and the relatively low commercial return compared with treatments for chronic conditions. Over the past decade, discovery and development have diversified across novel small molecules, next-generation analogues of existing classes, and adjunctive or host-directed strategies. While most candidates remain preclinical, several agents have advanced clinically in other infections, including gepotidacin (topoisomerase inhibitor; FDA-approved 2025 for urinary tract infection (UTI)), sulbactam\u2013durlobactam (DBO \u03b2-lactamase inhibitor; FDA-approved 2023 for Acinetobacter baumannii complex), and contezolid, supporting repurposing opportunities for NTM. Conversely, SPR720 (gyrase B prodrug) was suspended after not meeting its Phase 2 endpoint in 2024, underscoring translational risk. Overall, the NTM pipeline is expanding, with near-term progress most likely from repurposed agents and optimised combinations, alongside earlier-stage candidates that target biofilms or resistance mechanisms. This review aims to provide a critical and up-to-date overview of emerging antimicrobial strategies against NTM, highlighting recent advances, translational challenges, and opportunities to accelerate the development of effective therapeutics.<\/jats:p>","DOI":"10.3390\/antibiotics14121189","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T15:33:06Z","timestamp":1763739186000},"page":"1189","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Current Advances in Developing New Antimicrobial Agents Against Non-Tuberculous Mycobacterium"],"prefix":"10.3390","volume":"14","author":[{"given":"Jane","family":"Cross","sequence":"first","affiliation":[{"name":"Institute of Pharmaceutical Science, King\u2019s College London, 150 Stamford Street, London SE1 9NH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nupur","family":"Gargate","sequence":"additional","affiliation":[{"name":"Institute of Pharmaceutical Science, King\u2019s College London, 150 Stamford Street, London SE1 9NH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8566-8648","authenticated-orcid":false,"given":"Khondaker Miraz","family":"Rahman","sequence":"additional","affiliation":[{"name":"Institute of Pharmaceutical Science, King\u2019s College London, 150 Stamford Street, London SE1 9NH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"200299","DOI":"10.1183\/16000617.0299-2020","article-title":"The respiratory microbiome and nontuberculous mycobacteria: An emerging concern in human health","volume":"30","author":"Thornton","year":"2021","journal-title":"Eur. Respir. Rev."},{"key":"ref_2","unstructured":"(2024, December 20). Non-Tuberculous Mycobacterial Infection (NTM). Available online: https:\/\/www.asthmaandlung.org.uk\/conditions\/non-tuberculous-mycobacterial-ntm-infections."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2000535","DOI":"10.1183\/13993003.00535-2020","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: An official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"56","author":"Daley","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e01601-19","DOI":"10.1128\/AAC.01601-19","article-title":"THP-1 and Dictyostelium Infection Models for Screening and Characterization of Anti-Mycobacterium abscessus Hit Compounds","volume":"64","author":"Richter","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41579-020-0331-1","article-title":"Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus","volume":"18","author":"Johansen","year":"2020","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_6","first-page":"725","article-title":"Mycobacterium\u00a0kansasii","volume":"5","author":"Johnston","year":"2017","journal-title":"Microbiol. Spectr."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3346\/jkms.2010.25.2.304","article-title":"Disseminated Mycobacterium kansasii infection associated with skin lesions: A case report and comprehensive review of the literature","volume":"25","author":"Han","year":"2010","journal-title":"J. Korean Med. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e0033722","DOI":"10.1128\/jb.00337-22","article-title":"Mycobacterium smegmatis: The Vanguard of Mycobacterial Research","volume":"205","author":"Sparks","year":"2023","journal-title":"J. Bacteriol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"6904","DOI":"10.1128\/AAC.00459-15","article-title":"Susceptibility of Mycobacterium abscessus to Antimycobacterial Drugs in Preclinical Models","volume":"59","author":"Massoudi","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.tim.2023.11.011","article-title":"Modeling nontuberculous mycobacterial infections in zebrafish","volume":"32","author":"Johansen","year":"2024","journal-title":"Trends Microbiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.chest.2020.11.007","article-title":"You Gotta Make Me See, What Does It Mean to Have an MIC?","volume":"159","author":"Griffith","year":"2021","journal-title":"Chest"},{"key":"ref_12","unstructured":"Trust, W. (2025, August 26). The Growing Crisis for Antibiotic R&D. Available online: https:\/\/wellcome.org\/sites\/default\/files\/the-growing-crisis-for-antibiotic-r-and-d.pdf."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nbt.2786","article-title":"Clinical development success rates for investigational drugs","volume":"32","author":"Hay","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.5588\/ijtld.14.0120","article-title":"The epidemiologic relationship between tuberculosis and non-tuberculous mycobacterial disease: A systematic review","volume":"18","author":"Brode","year":"2014","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ijid.2022.10.013","article-title":"Global trends of pulmonary infections with nontuberculous mycobacteria: A systematic review","volume":"125","author":"Dahl","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s12223-025-01287-z","article-title":"Antimicrobial resistance mechanisms in non-tuberculous mycobacteria","volume":"70","author":"Tursun","year":"2025","journal-title":"Folia Microbiol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Nasiri, M.J., Haeili, M., Ghazi, M., Goudarzi, H., Pormohammad, A., Imani Fooladi, A.A., and Feizabadi, M.M. (2017). New Insights in to the Intrinsic and Acquired Drug Resistance Mechanisms in Mycobacteria. Front. Microbiol., 8.","DOI":"10.3389\/fmicb.2017.00681"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Saxena, S., Spaink, H.P., and Forn-Cun\u00ed, G. (2021). Drug Resistance in Nontuberculous Mycobacteria: Mechanisms and Models. Biology, 10.","DOI":"10.3390\/biology10020096"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Nguyen, T.Q., Heo, B.E., Jeon, S., Ash, A., Lee, H., Moon, C., and Jang, J. (2024). Exploring antibiotic resistance mechanisms in Mycobacterium abscessus for enhanced therapeutic approaches. Front. Microbiol., 15.","DOI":"10.3389\/fmicb.2024.1331508"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Bento, C.M., Gomes, M.S., and Silva, T. (2020). Looking beyond Typical Treatments for Atypical Mycobacteria. Antibiotics, 9.","DOI":"10.3390\/antibiotics9010018"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"To, K., Cao, R., Yegiazaryan, A., Owens, J., and Venketaraman, V. (2020). General Overview of Nontuberculous Mycobacteria Opportunistic Pathogens: Mycobacterium avium and Mycobacterium abscessus. J. Clin. Med., 9.","DOI":"10.3390\/jcm9082541"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Lee, D.G., Kim, H.J., Lee, Y., Kim, J.H., Hwang, Y., Ha, J., and Ryoo, S. (2022). 10-DEBC Hydrochloride as a Promising New Agent against Infection of Mycobacterium abscessus. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23020591"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"132057","DOI":"10.1016\/j.molstruc.2021.132057","article-title":"Benzoxaboroles: New emerging and versatile scaffold with a plethora of pharmacological activities","volume":"1252","author":"Dhawan","year":"2022","journal-title":"J. Mol. Struct."},{"key":"ref_24","first-page":"e02420-20","article-title":"A Leucyl-tRNA Synthetase Inhibitor with Broad-Spectrum Anti-Mycobacterial Activity","volume":"95","author":"Ganapathy","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e01577-19","DOI":"10.1128\/AAC.01577-19","article-title":"In Vitro Susceptibility Testing of GSK656 against Mycobacterium Species","volume":"64","author":"Dong","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_26","unstructured":"ClinicalTrials.gov (2024, April 30). A Study to Evaluate GSK656 in Tuberculosis, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03557281?intr=GSK656&rank=1."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e0066922","DOI":"10.1128\/aac.00669-22","article-title":"Activity of Tricyclic Pyrrolopyrimidine Gyrase B Inhibitor against Mycobacterium abscessus","volume":"66","author":"Madani","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"107278","DOI":"10.1016\/j.ijantimicag.2024.107278","article-title":"The novel drug candidate VOMG kills Mycobacterium abscessus and other pathogens by inhibiting cell division","volume":"64","author":"Degiacomi","year":"2024","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_29","unstructured":"GSK (2025, August 28). Gepotidacin Approved by US FDA for Treatment of Uncomplicated Urinary Tract Infections. Available online: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/blujepa-gepotidacin-approved-by-us-fda-for-treatment-of-uncomplicated-urinary-tract-infections\/."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e0056422","DOI":"10.1128\/aac.00564-22","article-title":"In Vitro and In Vivo Activity of Gepotidacin against Drug-Resistant Mycobacterial Infections","volume":"66","author":"Ahmad","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.ijantimicag.2017.12.001","article-title":"Cyclophostin and Cyclipostins analogues, new promising molecules to treat mycobacterial-related diseases","volume":"51","author":"Nguyen","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Sarrazin, M., Poncin, I., Fourquet, P., Audebert, S., Camoin, L., Denis, Y., Santucci, P., Spilling, C.D., Kremer, L., and Le Moigne, V. (2024). Cyclophostin and Cyclipostins analogues counteract macrolide-induced resistance mediated by erm(41) in Mycobacterium abscessus. J. Biomed. Sci., 31.","DOI":"10.1186\/s12929-024-01091-w"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1021\/acsinfecdis.9b00389","article-title":"Active Benzimidazole Derivatives Targeting the MmpL3 Transporter in Mycobacterium abscessus","volume":"6","author":"Raynaud","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1080\/14787210.2023.2270158","article-title":"Nontuberculous mycobacterial pulmonary disease and the potential role of SPR720","volume":"21","author":"Winthrop","year":"2023","journal-title":"Expert. Rev. Anti Infect. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1128\/AAC.04347-14","article-title":"A novel inhibitor of gyrase B is a potent drug candidate for treatment of tuberculosis and nontuberculosis mycobacterial infections","volume":"59","author":"Locher","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Pidot, S.J., Porter, J.L., Lister, T., and Stinear, T.P. (2021). In vitro activity of SPR719 against Mycobacterium ulcerans, Mycobacterium marinum and Mycobacterium chimaera. PLoS Negl. Trop. Dis., 15.","DOI":"10.1371\/journal.pntd.0009636"},{"key":"ref_37","unstructured":"ClinicalTrials.gov (2025, November 16). Study Details | NCT03796910 | A Study of the Safety, Tolerability, and Pharmacokinetics of SPR720 in Healthy Volunteers | ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03796910?term=spr720&viewType=Table&checkSpell=&rank=4."},{"key":"ref_38","unstructured":"Therapeutics, S. (2025, November 16). SPR720\u2014Spero Therapeutics. Available online: https:\/\/s3.amazonaws.com\/b2icontent.irpass.cc\/2748\/rl139704.pdf."},{"key":"ref_39","first-page":"875","article-title":"Efficacy of SPR720 in murine models of non-tuberculous mycobacterial pulmonary infection","volume":"79","author":"Cotroneo","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e0067621","DOI":"10.1128\/AAC.00676-21","article-title":"Piperidine-4-Carboxamides Target DNA Gyrase in Mycobacterium abscessus","volume":"65","author":"Negatu","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e02469-20","DOI":"10.1128\/AAC.02469-20","article-title":"The Benzimidazole SPR719 Shows Promising Concentration-Dependent Activity and Synergy against Nontuberculous Mycobacteria","volume":"65","author":"Pennings","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/mmi.13406","article-title":"A new piperidinol derivative targeting mycolic acid transport in Mycobacterium abscessus","volume":"101","author":"Dupont","year":"2016","journal-title":"Mol. Microbiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/open.202000042","article-title":"Structure-Based Design and Synthesis of Piperidinol-Containing Molecules as New Mycobacterium abscessus Inhibitors","volume":"9","author":"Dupont","year":"2020","journal-title":"ChemistryOpen"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.1128\/AAC.00331-15","article-title":"Gallium Compounds Exhibit Potential as New Therapeutic Agents against Mycobacterium abscessus","volume":"59","author":"Abdalla","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_45","unstructured":"ClinicalTrials.gov (2024, May 08). A Study of Gallium Nitrate in CF Patients with NTM, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04294043."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1128\/AAC.00320-12","article-title":"Identification of (+)-erythro-mefloquine as an active enantiomer with greater efficacy than mefloquine against Mycobacterium avium infection in mice","volume":"56","author":"Bermudez","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1128\/AAC.48.9.3556-3558.2004","article-title":"SRI-286, a thiosemicarbazole, in combination with mefloquine and moxifloxacin for treatment of murine Mycobacterium avium complex disease","volume":"48","author":"Bermudez","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Mann, L., Ganapathy, U.S., Abdelaziz, R., Lang, M., Zimmerman, M.D., Dartois, V., Dick, T., and Richter, A. (2022). In Vitro Profiling of the Synthetic RNA Polymerase Inhibitor MMV688845 against Mycobacterium abscessus. Microbiol. Spectr., 10.","DOI":"10.1128\/spectrum.02760-22"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1021\/acs.jmedchem.3c00009","article-title":"Synthesis and Characterization of Phenylalanine Amides Active against Mycobacterium abscessus and Other Mycobacteria","volume":"66","author":"Lang","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e316","DOI":"10.1016\/S2666-5247(23)00401-9","article-title":"Phase 2 trial of a novel tuberculosis drug launched","volume":"5","author":"Holt","year":"2024","journal-title":"The Lancet Microbe."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e02404","DOI":"10.1128\/AAC.02404-19","article-title":"TBAJ-876, a 3,5-Dialkoxypyridine Analogue of Bedaquiline, Is Active against Mycobacterium abscessus","volume":"64","author":"Sarathy","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_52","unstructured":"ClinicalTrials.gov (2025, November 16). Evaluation of the Safety, Tolerability, PK of TBAJ-587 in Healthy Adults, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04890535."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e0094524","DOI":"10.1128\/aac.00945-24","article-title":"TBAJ-587, a novel diarylquinoline, is active against Mycobacterium abscessus","volume":"68","author":"Fan","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e02418-20","DOI":"10.1128\/AAC.02418-20","article-title":"Comparative Efficacy of the Novel Diarylquinoline TBAJ-587 and Bedaquiline against a Resistant Rv0678 Mutant in a Mouse Model of Tuberculosis","volume":"65","author":"Xu","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Zhu, R., Shang, Y., Chen, S., Xiao, H., Ren, R., Wang, F., Xue, Y., Li, L., Li, Y., and Chu, N. (2022). In Vitro Activity of the Sudapyridine (WX-081) against Non-Tuberculous Mycobacteria Isolated in Beijing, China. Microbiol. Spectr., 10.","DOI":"10.1128\/spectrum.01372-22"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Nie, W., Gao, S., Su, L., Liu, L., Geng, R., You, Y., and Chu, N. (2023). Antibacterial activity of the novel compound Sudapyridine (WX-081) against Mycobacterium abscessus. Front. Cell Infect. Microbiol., 13.","DOI":"10.3389\/fcimb.2023.1217975"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"102655","DOI":"10.1016\/j.tube.2025.102655","article-title":"In vitro and in vivo antibacterial activity of sudapyridine (WX-081) combined with other drugs against Mycobacterium abscessus","volume":"154","author":"Wang","year":"2025","journal-title":"Tuberculosis"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.bmc.2014.12.019","article-title":"Synthesis and in vitro biological evaluation of 2-(phenylcarbamoyl)phenyl 4-substituted benzoates","volume":"23","author":"Baranyai","year":"2015","journal-title":"Bioorganic Med. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e0088921","DOI":"10.1128\/AAC.00889-21","article-title":"A Novel Oxazolidinone, Contezolid (MRX-I), Expresses Anti-Mycobacterium abscessus Activity In Vitro","volume":"65","author":"Guo","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_60","unstructured":"ClinicalTrials.gov (2025, September 10). Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis: Contezolid, Delamanid and Bedaquiline Cohort (INSPIRE-CODA), Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT06081361."},{"key":"ref_61","unstructured":"Trials, E.C. (2025, September 10). Study on the Safety and Effectiveness of Contezolid Acefosamil, Contezolid, and Linezolid for Adults with Moderate or Severe Diabetic Foot Infections. Available online: https:\/\/clinicaltrials.eu\/trial\/study-on-the-safety-and-effectiveness-of-contezolid-acefosamil-contezolid-and-linezolid-for-adults-with-moderate-or-severe-diabetic-foot-infections\/."},{"key":"ref_62","unstructured":"ClinicalTrials.gov (2025, August 30). Phase II, Multicenter, Randomized, Double-Blind Study Comparing Contezolid Acefosamil with Linezolid in Adults with Acute Bacterial Skin and Skin Structure Infections (ABSSSI), Available online: https:\/\/clinicaltrials.gov\/study\/NCT03747497."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e02752-16","DOI":"10.1128\/AAC.02752-16","article-title":"Activity of LCB01-0371, a Novel Oxazolidinone, against Mycobacterium abscessus","volume":"61","author":"Kim","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1016\/j.clinthera.2018.10.007","article-title":"Multiple-dose Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral LCB01-0371 in Healthy Male Volunteers","volume":"40","author":"Cho","year":"2018","journal-title":"Clin. Ther."},{"key":"ref_65","unstructured":"ClinicalTrials.gov (2025, August 30). A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02836483."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Madani, A., Mallick, I., Guy, A., Crauste, C., Durand, T., Fourquet, P., Audebert, S., Camoin, L., Canaan, S., and Cavalier, J.F. (2020). Dissecting the antibacterial activity of oxadiazolone-core derivatives against Mycobacterium abscessus. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0238178"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Batchelder, H.R., Story-Roller, E., Lloyd, E.P., Kaushik, A., Bigelow, K.M., Maggioncalda, E.C., Nuermberger, E.L., Lamichhane, G., and Townsend, C.A. (2020). Development of a penem antibiotic against Mycobacteroides abscessus. Commun. Biol., 3.","DOI":"10.1038\/s42003-020-01475-2"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Dousa, K.M., Nguyen, D.C., Kurz, S.G., Taracila, M.A., Bethel, C.R., Schinabeck, W., Kreiswirth, B.N., Brown, S.T., Boom, W.H., and Hotchkiss, R.S. (2022). Inhibiting Mycobacterium abscessus Cell Wall Synthesis: Using a Novel Diazabicyclooctane \u03b2-Lactamase Inhibitor To Augment \u03b2-Lactam Action. mbio, 13.","DOI":"10.1128\/mbio.03529-21"},{"key":"ref_69","unstructured":"Humphries, R.M. (2025, September 10). Sulbactam-Durlobactam: The \u201cDouble Beta-Lactamase Inhibitor\u201d Drug. Available online: https:\/\/clsi.org\/about\/news\/ast-news-update-january-2024-sulbactam-durlobactam-the-double-beta-lactamase-inhibitor-drug\/."},{"key":"ref_70","unstructured":"ClinicalTrials.gov (2025, August 30). Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex (ATTACK), Available online: https:\/\/clinicaltrials.gov\/study\/NCT03894046."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1128\/AAC.01545-09","article-title":"In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species","volume":"54","author":"Disratthakit","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Garcia, P.K., Annamalai, T., Wang, W., Bell, R.S., Le, D., Martin Pancorbo, P., Sikandar, S., Seddek, A., Yu, X., and Sun, D. (2019). Mechanism and resistance for antimycobacterial activity of a fluoroquinophenoxazine compound. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0207733"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"113668","DOI":"10.1016\/j.ejmech.2021.113668","article-title":"Design and synthesis of 2-(2-isonicotinoylhydrazineylidene)propanamides as InhA inhibitors with high antitubercular activity","volume":"223","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.tube.2019.03.002","article-title":"JVA, an isoniazid analogue, is a bioactive compound against a clinical isolate of the Mycobacterium avium complex","volume":"115","author":"Fahel","year":"2019","journal-title":"Tuberculosis"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Wang, X., Wan, M., Zhang, L., Dai, Y., Hai, Y., Yue, C., Xu, J., Ding, Y., Wang, M., and Xie, J. (2022). ALA_PDT Promotes Ferroptosis-Like Death of Mycobacterium abscessus and Antibiotic Sterilization via Oxidative Stress. Antioxidants, 11.","DOI":"10.3390\/antiox11030546"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Chen, C.H., and Lu, T.K. (2020). Development and Challenges of Antimicrobial Peptides for Therapeutic Applications. Antibiotics, 9.","DOI":"10.3390\/antibiotics9010024"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.resmic.2020.03.001","article-title":"Antimicrobial peptides against drug resistant Mycobacterium abscessus","volume":"171","author":"Gupta","year":"2020","journal-title":"Res. Microbiol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Sudadech, P., Roytrakul, S., Kaewprasert, O., Sirichoat, A., Chetchotisakd, P., Kanthawong, S., and Faksri, K. (2021). Assessment of in vitro activities of novel modified antimicrobial peptides against clarithromycin resistant Mycobacterium abscessus. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0260003"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Rao, K.U., Henderson, D.I., Krishnan, N., Puthia, M., Glegola-Madejska, I., Brive, L., Bjarnemark, F., Millqvist Fureby, A., Hjort, K., and Andersson, D.I. (2021). A broad spectrum anti-bacterial peptide with an adjunct potential for tuberculosis chemotherapy. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-83755-3"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Casanova, M., Maresca, M., Poncin, I., Point, V., Olleik, H., Boidin-Wichlacz, C., Tasiemski, A., Mabrouk, K., Cavalier, J.F., and Canaan, S. (2024). Promising antibacterial efficacy of arenicin peptides against the emerging opportunistic pathogen Mycobacterium abscessus. J. Biomed. Sci., 31.","DOI":"10.1186\/s12929-024-01007-8"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1038\/s12276-024-01339-3","article-title":"The inflammasome-activating poxvirus peptide IAMP29 promotes antimicrobial and anticancer responses","volume":"56","author":"Roh","year":"2024","journal-title":"Exp. Mol. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"23967","DOI":"10.1021\/acsomega.2c02844","article-title":"High-Throughput Screening Identifies Synthetic Peptides with Antibacterial Activity against Mycobacterium abscessus and Serum Stability","volume":"7","author":"Iannuzo","year":"2022","journal-title":"ACS Omega"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1021\/acsinfecdis.9b00041","article-title":"Modifications on C6 and C7 Positions of 3-Phenylquinolone Efflux Pump Inhibitors Led to Potent and Safe Antimycobacterial Treatment Adjuvants","volume":"5","author":"Felicetti","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"151855","DOI":"10.1016\/j.scitotenv.2021.151855","article-title":"Antibacterial peptide RP557 increases the antibiotic sensitivity of Mycobacterium abscessus by inhibiting biofilm formation","volume":"807","author":"Li","year":"2022","journal-title":"Sci. Total Environ."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jgar.2018.12.020","article-title":"Tetrahydropyridine derivative as efflux inhibitor in Mycobacterium abscessus","volume":"17","author":"Vianna","year":"2019","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4103\/ijmy.ijmy_167_18","article-title":"Antimicrobial properties of basidiomycota macrofungi to Mycobacterium abscessus isolated from patients with cystic fibrosis","volume":"8","author":"Millar","year":"2019","journal-title":"Int. J. Mycobacteriology"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Kim, H.W., Lee, J.W., Yu, A.R., Yoon, H.S., Kang, M., Lee, B.S., Park, H.W., Lee, S.K., Whang, J., and Kim, J.S. (2024). Isoegomaketone exhibits potential as a new Mycobacterium abscessus inhibitor. Front. Microbiol., 15.","DOI":"10.3389\/fmicb.2024.1344914"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/j.athoracsur.2006.01.031","article-title":"Early pulmonary resection for Mycobacterium avium complex lung disease treated with macrolides and quinolones","volume":"81","author":"Watanabe","year":"2006","journal-title":"Ann. Thorac. Surg."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/cid\/ciac453","article-title":"Phage Therapy of Mycobacterium Infections: Compassionate Use of Phages in 20 Patients With Drug-Resistant Mycobacterial Disease","volume":"76","author":"Dedrick","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2073132","DOI":"10.1080\/19490976.2022.2073132","article-title":"Arginine-mediated gut microbiome remodeling promotes host pulmonary immune defense against nontuberculous mycobacterial infection","volume":"14","author":"Kim","year":"2022","journal-title":"Gut Microbes"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Murthy, M.K., Gupta, V.K., and Maurya, A.P. (2025). Diagnosis of nontuberculous mycobacterial infections using genomics and artificial intelligence-machine learning approaches: Scope, progress and challenges. Front. Microbiol., 16.","DOI":"10.3389\/fmicb.2025.1665685"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s12539-024-00612-3","article-title":"Machine Learning Accelerates De Novo Design of Antimicrobial Peptides","volume":"16","author":"Yin","year":"2024","journal-title":"Interdiscip. Sci. Comput. Life Sci."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"102168","DOI":"10.1016\/j.tube.2022.102168","article-title":"Mycobacterium abscessus drug discovery using machine learning","volume":"132","author":"Schmalstig","year":"2022","journal-title":"Tuberculosis"},{"key":"ref_94","unstructured":"U.S. F.D.A (2025, August 31). Qualified Infectious Disease Product Designation Questions and Answers, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/qualified-infectious-disease-product-designation-questions-and-answers."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/12\/1189\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T15:42:42Z","timestamp":1763739762000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/12\/1189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":94,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["antibiotics14121189"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics14121189","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]}}}